Group 1 - The core viewpoint is that the chemical CDMO sector in China has significant advantages in talent, chemical capabilities, compliance capacity, and intellectual property protection, making it irreplaceable in the next five years [1] - The biopharmaceutical CDMO sector shows a clear industry beta, with companies in South Korea and Japan experiencing higher revenue growth compared to domestic firms, while the domestic leader WuXi AppTec is increasing its global market share in the CRDMO field [1] - The implementation of the Biological Safety Act is expected to lead to a valuation recovery in the CXO sector, indicating a long-term positive trend in China's innovative drug industry, particularly highlighted by explosive growth in BD transactions [1] Group 2 - The ETF Guotai (589720) tracks the Sci-Tech Innovation Drug Index (950161), which focuses on innovative R&D companies in the biopharmaceutical and chemical pharmaceutical sectors, reflecting the performance of growth-oriented companies driven by technological innovation in China's pharmaceutical industry [2]

Market Performance - Emerging markets continued to lead, with MSCI Global up by 1.5%, MSCI Developed Markets up by 1.1%, and MSCI Emerging Markets up by 4.2% [8][12] - In the developed markets, the South Korean Composite Index showed the strongest performance with an increase of 11.1%, while the Australian S&P 200 was the weakest, declining by 0.5% [8][12] - In the emerging markets, the Shanghai Composite Index performed best with a rise of 4.0%, while the Indian Sensex30 was the weakest, falling by 1.7% [8][12] Trading Sentiment - The volatility of major stock indices continued to rise, with trading volumes in various markets increasing significantly [25] - In Hong Kong, the short-selling ratio decreased to 14.7%, indicating a high investor sentiment, while North American sentiment remained at a historical high with the NAAIM manager exposure index rising to 97.7% [25][28] Earnings Expectations - The overall earnings expectations for Hong Kong stocks were revised downwards, with the Hang Seng Index's 2025 EPS forecast adjusted from 2072 to 2071 [71] - In contrast, Japanese stocks saw an upward revision in earnings expectations, with the Nikkei 225's 2025 EPS forecast increased from 2447 to 2451 [71][72] - The earnings expectations for the S&P 500 remained stable at 273, while the Eurozone STOXX50's forecast was revised down from 332 to 331 [71][72] Economic Expectations - Economic indicators showed a slight decline in the US and China, with the Citigroup Economic Surprise Index for the US decreasing due to mixed non-farm data and political uncertainties [8][71] - The Eurozone's Economic Surprise Index saw a slight increase, influenced by easing geopolitical tensions and changes in trade policies [8][71] Fund Flows - The probability of a Federal Reserve rate cut in January was significantly reduced, with market expectations for 2.1 rate cuts in 2026, a slight decrease from the previous week [58][59] - Global liquidity showed signs of tightening, with significant inflows into Hong Kong stocks, amounting to 167 billion HKD, despite some outflows from stable foreign capital [68][70]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has seen a rise of 1.48% as of January 14, 2026, with a turnover of 2.21% and a transaction volume of 37.37 million yuan [1] - The ETF's latest scale reached 1.671 billion yuan and the latest share count reached 1.883 billion, both hitting record highs since its inception [1] - The 44th JPMorgan Healthcare Conference is being held from January 12 to 15, 2026, in San Francisco, focusing on biotechnology, biopharmaceuticals, and AI in medicine, marking it as a significant investment and trading window for the global pharmaceutical industry [1] Group 2 - Yilian Biotech announced a new exclusive licensing agreement with Roche for the YL201 project, which includes an upfront payment of $570 million and potential milestone payments [2] - Haizhi Science signed a licensing agreement with AirNexis for the HSK39004 project, with a total transaction value exceeding $1 billion, currently in Phase II clinical trials in China [2] - Zhongsheng Peptide has reached a global licensing and collaboration agreement with Novartis for an undisclosed peptide asset in the field of radioligand therapy [2] Group 3 - The Hong Kong Stock Connect Innovative Drug Index aims to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [3] - The top ten weighted stocks in the index include CSPC Pharmaceutical Group, BeiGene, CanSino Biologics, China National Pharmaceutical Group, Innovent Biologics, 3SBio, Hansoh Pharmaceutical, Kelun-Biotech, Kangzheng Pharmaceutical, and Ascentage Pharma-B [3]

Group 1 - The Hong Kong stock market saw a strong performance in the early session on January 14, with the pharmaceutical sector leading the gains. The Hong Kong Innovative Drug ETF (159567) rose by 2.52%, with trading volume quickly surpassing 300 million yuan [1] - The Hong Kong Innovative Drug ETF (159567) has experienced a rebound since the beginning of 2026, with a cumulative increase of over 11% from January 5 to January 13 [1] - The ETF closely tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index (987018), which reflects the performance characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1] Group 2 - On January 12, the 44th JPMorgan Global Healthcare Conference officially opened in the United States, attracting significant attention from the biopharmaceutical industry. Several domestic innovative drug companies participated, with seven companies presenting at the main venue [2] - Huatai Securities noted that the liquidity in the Hong Kong innovative drug sector has significantly improved since the beginning of 2026, and the JPMorgan conference has provided a platform for domestic pharmaceutical companies to advance overseas business development (BD) collaborations [2] - The ongoing liquidity recovery is expected to lead to a clear innovative drug beta market, with external demand-driven CXO companies likely to achieve performance that exceeds expectations, resonating with innovative drugs [2]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak price of 2.88% and currently up by 2.52% [1] - Key performing stocks within the ETF include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1] - The market anticipates more international collaboration opportunities for Chinese innovative drug companies following the JPM Healthcare Conference held from January 12 to 15, 2026 [2][3] Group 2 - West Securities predicts that the Hong Kong innovative drug sector will continue to show structural trends in 2026, with accelerated BD (business development) overseas driving the convergence of drug price differences between China and the U.S. [3] - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [3] - The top ten weighted stocks in the Hang Seng Stock Connect Innovative Drug Select Index include Kangfang Biologics, CSPC Pharmaceutical Group, BeiGene, and China Biologic Products [3]

Core Insights - The medical device ETF (159873) has shown strong trading activity with a turnover of 26.84% and a transaction volume of 36.34 million yuan, while the underlying index, the CSI All Share Healthcare Equipment and Services Index (H30178), increased by 1.09% [1] - The innovative drug ETF Tianhong (517380) also performed well, with a turnover of 5.36% and a transaction volume of 95.97 million yuan, tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index (HSSSHID), which rose by 2.21% [1] - Both ETFs reached new highs in terms of scale and shares as of January 13, 2026, with the medical device ETF achieving a record scale and share, while the innovative drug ETF reached a scale of 1.807 billion yuan and 2.162 billion shares [2][3] Fund Flows - The medical device ETF (159873) has seen a net inflow of 26.50 million yuan over the past four days [1] - The innovative drug ETF Tianhong (517380) experienced a net inflow of 264 million yuan over the last six days [3] Product Highlights - The medical device ETF (159873) has a high concentration in brain-computer interface technology, accounting for over 19%, with nearly 80% of its components from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - The innovative drug ETF Tianhong (517380) targets opportunities in the innovative drug sector, benefiting from the concentration of top component stocks like WuXi AppTec and Hengrui Medicine, alongside the growth in BD transactions and breakthroughs in AI drug development [4] Industry Events - Qiangnao Technology, a brain-computer interface company, has submitted a confidential IPO application for listing on the Hong Kong Stock Exchange, potentially becoming the first listed company in China's brain-computer interface sector [4] - The company has completed approximately 2 billion yuan in financing, marking the second-largest financing event globally in the brain-computer interface field, excluding Neuralink [4][5] Institutional Perspectives - Analysts from Changcheng Guorui Securities view brain-computer interfaces as a forward-looking direction under the 14th Five-Year Plan, with several recommended industry standards being established to promote technological standardization and clinical registration processes [5]

Market Overview - The market experienced a decline on January 13, with the Shanghai Composite Index falling by 0.64%, the Shenzhen Component Index dropping by 1.37%, and the ChiNext Index decreasing by 1.96% [2] - The total trading volume reached 3.7 trillion yuan, an increase of approximately 60 billion yuan compared to the previous trading day [1] Sector Performance - Most sectors saw declines, with notable exceptions in oil, pharmaceuticals, and non-ferrous metals, while aerospace, electronics, communications, and computers faced the largest drops [1] - The aerospace sector's significant adjustment was influenced by multiple companies announcing share reductions, although this adjustment is not seen as severe compared to previous gains [1] Investment Opportunities - Despite the downturn in the aerospace sector, the overall market did not exhibit panic, with over 90 companies experiencing declines of 10% or more, primarily from the aerospace sector [1] - There is potential for short-term investment in other technology sectors, such as innovative pharmaceuticals and AI applications, as recent large-scale business development transactions in domestic innovative pharmaceutical companies indicate a high level of activity in this area [1] Policy Developments - The Ministry of Civil Affairs is working on measures to promote the silver economy, focusing on elderly care services, rehabilitation aids, and age-friendly products, aiming to optimize industry layout and attract social capital [3][5] - The Ministry of Industry and Information Technology has released an action plan for the high-quality development of industrial internet platforms, targeting the establishment of over 450 influential platforms by 2028 [4] Fund Dynamics - The first domestic fund management company has surpassed 1 trillion yuan in ETF assets, marking a significant milestone in the Chinese ETF market [10] - As of January 12, the total trading volume of ETFs reached 465.79 billion yuan, with stock ETFs accounting for 256.06 billion yuan of this total [12]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak of 2.88% and currently up by 2.52% [1][4]. Group 1: ETF Performance - The ETF's price reached a high of 0.577, with a current price of 0.569, reflecting a gain of 0.014 or 2.52% [2][6]. - The trading volume for the ETF was reported at 178,084 shares, with a turnover rate of 3.73% [6]. Group 2: Component Stocks - Notable performers among the ETF's component stocks include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1][5]. - Conversely, the stocks of Jiujiu Bio and Ascletis Pharma showed significant declines [1][5]. Group 3: Market Expectations - The JPM Healthcare Conference, held from January 12 to 15, 2026, has generated market anticipation regarding business development (BD) transaction data from Chinese innovative pharmaceutical companies, suggesting potential for increased international collaboration [6][7]. - The approval of updated labeling for the PD-1/VEGF dual antibody by the National Medical Products Administration for Kangfang Biopharma is expected to enhance treatment options for non-small cell lung cancer, indicating significant survival benefits [6][7]. Group 4: Industry Outlook - According to Western Securities, the innovative drug sector in Hong Kong is expected to maintain a structural market trend in 2026, with accelerated BD activities narrowing the price gap between Chinese and U.S. innovative drugs, leading to substantial long-term growth potential [7]. - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [7].

Core Viewpoint - The pharmaceutical sector in Hong Kong and A-shares experienced a significant surge, driven by various sub-sectors including innovative drugs, CRO, bioproducts, and medical services, leading to a wave of stock price increases [1][2][3] Group 1: Market Performance - A-shares saw a surge with stocks like Xin Gan Jiang, Nuo Si Ge, and Rong Chang Bio hitting the daily limit, while others like San Yuan Gene and Qian Yuan Pharma also reported substantial gains [1][2] - In the Hong Kong market, leading stocks such as WuXi AppTec and others also experienced notable increases, with WuXi AppTec rising over 7% [2][3] Group 2: Business Development (BD) Collaborations - The recent JPMorgan Healthcare Conference served as a key platform for Chinese innovative pharmaceutical companies to showcase their core products and advance overseas BD collaborations [5][6] - A series of significant BD deals were announced, including a $6.5 billion upfront payment agreement between Rong Chang Bio and AbbVie, with potential total payments reaching $5.6 billion [7] - Other notable collaborations included a $5.7 billion deal between Yilian Bio and Roche, and a nearly $1.7 billion agreement between Sino Neuro and Novartis [7] Group 3: Financial Performance - WuXi AppTec projected a revenue of approximately 45.456 billion yuan for 2025, marking a year-on-year increase of about 15.84%, with a net profit expected to reach 19.151 billion yuan, reflecting a significant growth of approximately 103% [9] - BeiGene also reported strong revenue expectations for 2025, estimating between 36.2 billion to 38.1 billion yuan, indicating substantial growth compared to the previous year [12] Group 4: Industry Outlook - Analysts are optimistic about the long-term prospects of the innovative drug sector, with expectations of continued BD activity and a peak in data disclosures in early 2026 [14] - The trend of Chinese innovative drugs entering overseas markets is expected to persist, with a focus on clinical progress and data realization [14] - The ADC (Antibody-Drug Conjugate) sector is highlighted as a rapidly developing treatment modality, with high technical barriers and strong customer loyalty in the CDMO (Contract Development and Manufacturing Organization) industry [16]

Core Insights - The current market perception equates "investing in technology" with "buying AI," with popular sectors like optical modules seen as entry points into the AI trend [1] - Zhang Jiansheng, a fund manager at Baodao Fund, adopts a unique investment style that focuses on early-stage opportunities rather than chasing hot stocks, achieving significant returns [1][2] - His fund, Baodao Shengyan A, reported over 45% annual returns in 2025 and a cumulative return of over 65% in three years, showcasing strong mid-to-long-term performance [1] Investment Strategy - Zhang's investment framework emphasizes a "bottom-up" approach, moderate industry diversification, and a balanced growth focus, with a strong emphasis on valuation and drawdown control [2][3] - He maintains a cautious risk preference shaped by his early career experiences during market volatility, leading to a left-side trading characteristic where he buys and sells based on predetermined market cap targets [1][2] Stock Selection Criteria - Zhang's stock selection is guided by three main dimensions: competitive barriers, industry prosperity, and valuation, with a particular focus on avoiding high premium valuations in the TMT sector [2] - He prefers to invest in lesser-known stocks with lower valuations and moderate market attention, allowing for a more controlled downside risk [2][4] Portfolio Construction - The portfolio is diversified across high-end manufacturing, TMT, and consumer sectors, with no single industry exceeding 25% of holdings, resulting in better drawdown control compared to peers [3] - Zhang's strategy includes a tiered approach to portfolio construction, where some positions are taken on the left side while waiting for clearer signals on the right side [4] Market Outlook for 2026 - Zhang holds an optimistic view on the A-share market, supported by three key factors: a significant decrease in risk premiums, ongoing regulatory support for capital markets, and signs of corporate earnings recovery [5] - Investment focus areas for 2026 include AI, particularly in storage and connectivity sectors, as well as traditional industries like chemicals and consumer sectors where valuation recovery opportunities exist [5][6]